Business Context and Reporting Period
This Form 8-K filing by CorMedix Inc. (Delaware) covers the event date of August 11, 2011. The report details corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
- Board Election: Steven W. Lefkowitz was elected as a director to serve until the 2012 annual meeting of stockholders.
- Committee Assignments: Mr. Lefkowitz was appointed to the Audit Committee and the Compensation Committee.
- Appointment Authority: The election was made pursuant to rights held by Shiva Biomedical, LLC under a Contribution Agreement, which allows Shiva to appoint a representative to the Board.
Compensation and Outlook
Compensatory Arrangements:
- Stock Options: Mr. Lefkowitz received an initial grant of options to purchase 30,000 shares of common stock at an exercise price of $1.10 per share (closing price on August 11, 2011). The options have a ten-year term and vest one-third on the grant date, with the remaining balance vesting on the first and second anniversaries.
- Director Retainers: Mr. Lefkowitz is entitled to pro-rated portions of the following annual retainers: $20,000 for director service, $5,000 for Audit Committee service, and $4,000 for Compensation Committee service.
Outlook and Risks: The filing contains no management commentary regarding future business outlook, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the terms of the Contribution Agreement between CorMedix Inc. and Shiva Biomedical, LLC regarding board representation rights.
- Confirm the vesting schedule and exercise price of the 30,000 stock options granted to Steven W. Lefkowitz.
- Review the attached press release (Exhibit 99.1) for additional context on the director's background.